Insider trade

Officer sold ~$1.01M of LLY shares in the open market

Traded Nov 13, 2025 · Filed Nov 13, 2025

Eli LillyLLY

~$1.01M
Reported value · 1,000 sh @ $1,010.50: 2,839.66
Holds after · shares reported: +12.4%
stock since the trade · S&P 500 +13.7%, $1,022.87 → $1,149.85 on Oct 1

Why it stands out

Eli Lilly's SVP, Finance, & CAO sold $1.01M of Eli Lilly shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 13, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 13, 2025

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,010,500

Shares × reported transaction price

Timing vs results

14 days after results of Oct 30, 2025, 83 days before results of Feb 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $1,022.87 on Nov 13, 2025, at its 52-week high, after a 25% rise over the previous 30 trading days

52-week range $625.65 (Aug 8, 2025) to $1,022.87 (Nov 13, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $819.85 on Oct 2, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Retevmo on Nov 20, 2025, 7 days after this trade.

New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.4%	-1.9%	+5.3%
30 days	+3.6%	+1.3%	+2.3%
90 days	+1.3%	+1.4%	-0.1%
180 days	-0.9%	+10.5%	-11.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001561539-25-000006
Filed / recorded: Nov 13, 2025, 9:14 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: ELI LILLY & Co
Issuer CIK: 59478
Ticker: LLY
Reporting person: Donald A Zakrowski
Relationship: Officer
Officer title: SVP, Finance, & CAO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 13, 2025
Transaction code: S
Shares / units: 1,000
Price per share: $1,010.50
Acquired / disposed: Disposed (D)
Shares owned after: 2,839.659
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2024.

Around the same time

10mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

9 different filers disclosed LLY within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

10mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

9 different filers disclosed LLY within 90 days. Disclosed 17 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

Major shareholder sold10mo ago

~$862KReported value · 800 sh @ $1,077.988

92.4M → 92.4M shares held

A big owner of Eli Lilly sold $862K of Eli Lilly shares. Nobody planned it ahead of time.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Footnotes from the filing

Around the same time

$1,001 - $15,000Reported range · official band, not an exact amount

$1,001 - $15,000Reported range · official band, not an exact amount

~$862KReported value · 800 sh @ $1,077.988

Most active this month